(Q39522086)

12 September 2017

Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice (English)

1 reference

12 September 2017

6

G Giovannoni

1 reference

12 September 2017

R A Farrell

1

1 reference

12 September 2017

M Espasandin

2

1 reference

12 September 2017

N Lakdawala

3

1 reference

12 September 2017

P I Creeke

4

1 reference

12 September 2017

V Worthington

5

1 reference

12 September 2017

17 June 2011

1 reference

Multiple Sclerosis Journal

12 September 2017

1 reference

12 September 2017

17

1 reference

12 September 2017

11

1 reference

12 September 2017

1333-1340

1 reference

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

12 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511412654

21 January 2018

Identifiers

DOI

10.1177/1352458511412654

1 reference

12 September 2017

1 reference